Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease

NCT06388083 is registered in ClinicalTrials.gov with Belite Bio, Inc as lead sponsor.

NCT NCT06388083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06388083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease
Lead sponsor
Belite Bio, Inc
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
July 31, 2024
Completion date
February 29, 2028
Enrollment
60 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

stargardt disease 1, stgd1